Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of 1 of the following:~  * Acute lymphoblastic leukemia (ALL) OR acute myeloid leukemia (AML)~    * At least 25% blasts in the bone marrow~   * Recurrent or refractory disease~ * Non-Hodgkin's lymphoma (NHL)~    * Second or greater relapse as determined by physical or radiological evidence~* Disease for which there is no known curative therapy~PATIENT CHARACTERISTICS:~Age~* 21 and under~Performance status~* Karnofsky 50-100% (patients over 10 years of age)~* Lansky 50-100% (patients 10 years of age and under)~Life expectancy~* At least 4 weeks~Hematopoietic~* Absolute neutrophil count at least 1,000/mm\^3\*~* Platelet count at least 75,000/mm\^3 (transfusion independent)\*~* Hemoglobin at least 8.0 g/dL (may receive red blood cells (RBC) transfusions)\* NOTE: \*Patients with ALL, AML, and NHL with tumor metastatic to bone marrow, with granulocytopenia, anemia, and/or thrombocytopenia are eligible, but will not be evaluable for hematological toxicity~Hepatic~* Bilirubin no greater than 1.5 times normal~* alanine aminotransferase (ALT) no greater than 5 times normal~* Albumin at least 2 g/dL~Renal~* Creatinine based on age, as follows:~  * No greater than 0.8 mg/dL (5 years of age and under)~ * No greater than 1.0 mg/dL (6 to 10 years of age)~ * No greater than 1.2 mg/dL (11 to 15 years of age)~ * No greater than 1.5 mg/dL (over 15 years of age) OR~* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min~Cardiovascular~* Shortening fraction at least 28% by echocardiogram OR~* Ejection fraction at least 50% by gated radionuclide~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to ingest oral medication~* No known allergy to sirolimus, tacrolimus, or other mammalian target of rapamycin (mTOR) inhibitors~* No uncontrolled active infection~  * Fungal disease must be stable for at least 2 weeks prior to study entry~ * Documented negative blood cultures prior to study entry for patients with bacteremia~* No active graft-versus-host disease~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Recovered from prior immunotherapy~* More than 1 week since prior hematopoietic growth factors except for epoetin alfa~* At least 7 days since prior biologic antineoplastic agents~* At least 3 months since prior bone marrow or stem cell transplantation~Chemotherapy~* Recovered from all prior chemotherapy~* More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)~* Prior hydroxyurea within the past 2 weeks is allowed provided peripheral blast count has been stable or rising for at least 3 days~Endocrine therapy~* Prior corticosteroids within the past 2 weeks are allowed provided peripheral blast count has been stable or rising for at least 3 days~Radiotherapy~* Recovered from prior radiotherapy~* At least 2 weeks since prior local palliative radiotherapy~* At least 4 weeks since prior craniospinal radiotherapy or radiation to the pelvis of 50% or more~* At least 4 weeks since prior substantial bone marrow radiotherapy~* No concurrent radiotherapy, except for emergent situations or persistent extramedullary disease with resolution of bone marrow disease~Surgery~* Not specified~Other~* No other concurrent investigational antineoplastic drugs~* No concurrent administration of any of the following:~  * Ketoconazole~ * Tacrolimus~ * Cyclosporine~ * Rifampin~ * Diltiazem

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose

Based on this trial design, predict the completion outcome and termination type (if applicable).